These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10530584)

  • 21. Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys.
    Emary WB; Toren PC; Mathews B; Huh K
    Drug Metab Dispos; 1998 Aug; 26(8):725-31. PubMed ID: 9698285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.
    Zurlinden TJ; Eppers GJ; Reisfeld B
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4860-8. PubMed ID: 27270284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.
    Francis J; Zvada SP; Denti P; Hatherill M; Charalambous S; Mungofa S; Dawson R; Dorman S; Gupte N; Wiesner L; Jindani A; Harrison TS; Olagunju A; Egan D; Owen A; McIlleron HM
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
    Dorman SE; Savic RM; Goldberg S; Stout JE; Schluger N; Muzanyi G; Johnson JL; Nahid P; Hecker EJ; Heilig CM; Bozeman L; Feng PJ; Moro RN; MacKenzie W; Dooley KE; Nuermberger EL; Vernon A; Weiner M;
    Am J Respir Crit Care Med; 2015 Feb; 191(3):333-43. PubMed ID: 25489785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
    Dooley K; Flexner C; Hackman J; Peloquin CA; Nuermberger E; Chaisson RE; Dorman SE
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4037-42. PubMed ID: 18765687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I.
    Keung A; Reith K; Eller MG; McKenzie KA; Cheng L; Weir SJ
    Int J Tuberc Lung Dis; 1999 May; 3(5):426-36. PubMed ID: 10331733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
    Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
    Hibma JE; Radtke KK; Dorman SE; Jindani A; Dooley KE; Weiner M; McIlleron HM; Savic RM
    Am J Respir Crit Care Med; 2020 Sep; 202(6):866-877. PubMed ID: 32412342
    [No Abstract]   [Full Text] [Related]  

  • 29. [In vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosis].
    Duanmu HJ; Liu YH; Jiang GL; Wang SM; Fu YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):192-4. PubMed ID: 15854417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder.
    Chan JG; Tyne AS; Pang A; McLachlan AJ; Perera V; Chan JC; Britton WJ; Chan HK; Duke CC; Young PM; Traini D
    Int J Antimicrob Agents; 2015 Mar; 45(3):319-23. PubMed ID: 25554469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs.
    Dutta NK; Alsultan A; Peloquin CA; Karakousis PC
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1535-7. PubMed ID: 23295923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.
    Savic RM; Weiner M; MacKenzie WR; Engle M; Whitworth WC; Johnson JL; Nsubuga P; Nahid P; Nguyen NV; Peloquin CA; Dooley KE; Dorman SE;
    Clin Pharmacol Ther; 2017 Aug; 102(2):321-331. PubMed ID: 28124478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.
    Dooley KE; Savic RM; Park JG; Cramer Y; Hafner R; Hogg E; Janik J; Marzinke MA; Patterson K; Benson CA; Hovind L; Dorman SE; Haas DW;
    Antimicrob Agents Chemother; 2015; 59(6):3399-405. PubMed ID: 25824215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers.
    Pargal A; Rani S
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):70-9. PubMed ID: 11263520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
    Weiner M; Burman W; Vernon A; Benator D; Peloquin CA; Khan A; Weis S; King B; Shah N; Hodge T;
    Am J Respir Crit Care Med; 2003 May; 167(10):1341-7. PubMed ID: 12531776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
    Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
    Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.
    Borin MT; Chambers JH; Carel BJ; Gagnon S; Freimuth WW
    Clin Pharmacol Ther; 1997 May; 61(5):544-53. PubMed ID: 9164416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?
    Zheng C; Hu X; Zhao L; Hu M; Gao F
    Drug Des Devel Ther; 2017; 11():2957-2968. PubMed ID: 29066867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.